RNA Analysis Market

RNA Analysis Market by Product (Reagents, Instruments, Software, Services), Technology (PCR, Sequencing, Microarrays, RNA Interference), Application (Drug Discovery, Clinical Diagnostics), End User (Pharma, Biotech, CROs), Region - Global Forecast to 2028

Report Code: BT 2766 Jul, 2023, by marketsandmarkets.com

The global RNA analysis market in terms of revenue was estimated to be worth $5.3 billion in 2023 and is poised to reach $9.9 billion by 2028, growing at a CAGR of 13.4% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Various elements such as increasing R&D activities, increasing government funding for drug discovery research, and growing pharmaceutical & biological industries are the major growth factors for this market. Many peptide-based research projects are also being fostered by increasing collaborative partnerships among various companies that are driving market growth.

Attractive Opportunities in the RNA analysis Market

RNA analysis Market

To know about the assumptions considered for the study, Request for Free Sample Report

RNA analysis Market

RNA Analysis Market Dynamics

DRIVER: Growing demand for personalized medicine

With the growing prominence of personalized medicine, there is an increased demand for rapid, highly sensitive, and quantitative methods to analyze proteins and related post-translational modifications in clinical specimens. In addition, as gene variants predict a patient’s likely response to a certain medication, researchers are increasingly focusing on identifying and studying various proteins, modifications, genetic variants, and their relevance to different diseases. Advances in omics technologies have made important contributions to the development of personalized medicine by facilitating the detection of protein biomarkers, proteomics-based molecular diagnostics, as well as pharmacoproteomics.

RESTRAINT: High capital investments

Advancements in various instruments have led to higher prices than previous-generation instruments due to their expensive development process. For instance, in 2022, an Illumina HiSeq X Ten sequencing instrument cost USD 1 million. In 2021, the cost of the same instrument was USD 750,000. Companies rely on accessible structural data and trial-and-error methods to determine the compounds that either stimulate or disable targets. All processes need a large number of laboratory hours, thus increasing the per-sample testing cost. Such high prices of instruments and reagents make it difficult for developing countries to venture into the field of transcriptomics. The high costs involved have led to the lower-than-expected adoption of transcriptomic technologies across the globe.

OPPORTUNITY: Opportunities in Emerging Countries

The focus on omics research has increased in developing countries like China, Brazil, Australia, and India. In these countries, proteomics research is mainly focused on mapping the human proteome and determining the mechanism of action of drugs. The establishment of the Proteomics Society, India (PSI) has provided proteomic scientists and researchers in the country with significant opportunities to form research collaborations and conduct workshops on proteomics. Similarly, increasing competition in mature markets also compels manufacturers to focus on emerging markets to ensure stable revenue growth in the coming years. Thus, although transcriptomics research is concentrated in the US and other developed countries across Europe, over the last decade, developing countries across the world have emerged as growth avenues for life sciences, including transcriptomics research.

CHALLENGE: Data management in transcriptomics research

Transcriptomics is a rapidly expanding field, aided by instrumentation accuracy and sensitivity, size, and affordability improvements. This offers many possibilities for personalized and precision medicine, which could improve diagnosis, treatment, and disease management in the coming years. However, with the increase in transcriptome and subsequent genomic analysis, there is an inevitable increase in the volume of data generated. These are just a few of the complexities involved in the data management of transcriptomics. Also, the lack of competent databases for data storage, comparing transcriptomic data, and the in-depth analysis of experimental results are further inhibiting the growth of this market.

RNA Analysis Market Ecosystem

RNA analysis Market Ecosystem

The Reagents/Consumables segment dominated RNA analysis industry in 2022

Based on product & service, the RNA analysis market is segmented into reagent/consumables, instruments, software, and services. In 2022, the reagents/consumables segment accounted for the largest share of the market. The large share of this segment can be attributed to the growth of RNA analysis reagents is fueled by the increase in demand of genome based studies, technological advancements; and the availability of various RNA analysis reagents in the market.

North America dominated the RNA analysis industry in 2022.

RNA analysis Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Geographically, the RNA analysis market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2022, North America accounted for the largest share of the market, followed by Europe and the Asia Pacific. The large share of the North American market is owing to various factors such presence of a large number of pharmaceutical companies and the growing demand for personalized medicines. Increased funding for protein-based research is furthermore driving market growth in North America.

Key players in the RNA analysis market are Thermo Fisher Scientific, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), Illumina, Inc. (US), Eurofins Scientific (Luxembourg)

Scope of the RNA Analysis Industry

Report Metric 

Details 

Market Revenue in 2023

$5.3 billion

Projected Revenue by 2028

$9.9 billion

Revenue Rate

Poised to Grow at a CAGR of 13.4%

Market Driver

Growing demand for personalized medicine

Market Opportunity

Opportunities in Emerging Countries

This report categorizes the RNA analysis market to forecast revenue and analyze trends in each of the following submarkets:

By Product & Service

  • Reagents/Consumables
  • Instrument
  • Software
  • Services

By Technology

  • Polymerase Chain Reaction (PCR)
  • Microarrays
  • Sequencing
  • RNA Interference

By Application

  • Drug Discovery
  • Clinical Diagnostics
  • Toxicogenomics
  • Comparative Transcriptomics

By End User

  • Pharmaceutical & Biotechnology Company
  • Hospitals & Diagnostic Centers
  • Academic & Research Institutes
  • CROs

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Switzerland
    • Rest of Europe (RoE)
  • Asia Pacific (APAC)
    • China
    • Japan
    • India
    • Rest of Asia Pacific (RoAPAC)
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

Recent Developments by RNA Analysis Industry

  • In October 2022, Agilent Technologies and CMP Scientific Corp. entered into a co-marketing agreement to provide an integrated capillary electrophoresis-mass spectrometry (CE-MS) solution for the life science and pharmaceutical industries.
  • In March 2022, Eurofins acquired Beacon Discovery, a drug discovery-based CRO. Beacon supported the fully integrated drug discovery programs from target validation to pre-clinical candidates.
  • In January 2021, Thermo Fisher acquired Phitonex to provide greater flow cytometry and imaging multiplexing capabilities for protein and cell analysis research needs. Phitonex’s product offerings are also an expansion of the company’s existing protein and cell analysis portfolio.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 28)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 MARKET SCOPE 
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED
    1.4 CURRENCY 
    1.5 LIMITATIONS 
    1.6 STAKEHOLDERS 
    1.7 SUMMARY OF CHANGES 
           1.7.1 RECESSION IMPACT
 
2 RESEARCH METHODOLOGY (Page No. - 32)
    2.1 RESEARCH DATA 
          FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                    FIGURE 2 RNA ANALYSIS MARKET: BREAKDOWN OF PRIMARIES
    2.2 MARKET SIZE ESTIMATION 
          FIGURE 3 RNA ANALYSIS INDUSTRY SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS (2022)
          FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022
          FIGURE 5 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE ANALYSIS, 2022
           2.2.1 INSIGHTS FROM PRIMARIES
                    FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS
           2.2.2 SEGMENT ASSESSMENT (BY PRODUCT, TECHNOLOGY, APPLICATION, AND END USER)
                    FIGURE 7 RNA ANALYSIS INDUSTRY SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
    2.3 GROWTH RATE ASSUMPTIONS 
          FIGURE 8 MARKET: CAGR PROJECTIONS, 2023–2028
          FIGURE 9 MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 10 DATA TRIANGULATION METHODOLOGY
    2.5 STUDY ASSUMPTIONS 
    2.6 RISK ANALYSIS 
    2.7 IMPACT OF ECONOMIC RECESSION ON MARKET 
          TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2024–2028 (% GROWTH)
          TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
          TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)
 
3 EXECUTIVE SUMMARY (Page No. - 44)
    FIGURE 11 RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)
    FIGURE 12 RNA ANALYSIS INDUSTRY, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
    FIGURE 13 RNA ANALYSIS INDUSTRY, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    FIGURE 14 RNA ANALYSIS INDUSTRY, BY END USER, 2023 VS. 2028 (USD MILLION)
    FIGURE 15 GEOGRAPHICAL SNAPSHOT: RNA ANALYSIS INDUSTRY 
 
4 PREMIUM INSIGHTS (Page No. - 50)
    4.1 RNA ANALYSIS MARKET OVERVIEW 
          FIGURE 16 RISING INVESTMENTS IN PHARMACEUTICAL R&D TO DRIVE MARKET GROWTH
    4.2 NORTH AMERICA: MARKET SHARE, BY APPLICATION & COUNTRY (2022) 
          FIGURE 17 DRUG DISCOVERY APPLICATIONS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022
    4.3 RNA ANALYSIS INDUSTRY SHARE, BY END USER, 2022 
          FIGURE 18 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
    4.4 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 19 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN MARKET FROM 2023 TO 2028
    4.5 MARKET, BY REGION (2023–2028) 
          FIGURE 20 NORTH AMERICA TO CONTINUE TO DOMINATE MARKET UNTIL 2028
    4.6 MARKET: DEVELOPED VS. EMERGING ECONOMIES 
          FIGURE 21 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 56)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 22 MARKET DYNAMICS: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
          TABLE 4 RNA ANALYSIS MARKET: IMPACT ANALYSIS
           5.2.1 DRIVERS
                    5.2.1.1 Growing demand for personalized medicine
                                FIGURE 23 PERSONALIZED MEDICINES APPROVED BY FDA, 2015–2022
                    5.2.1.2 Rising pharmaceutical and biotechnology R&D expenditure and government funding
                                FIGURE 24 INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2012–2026
                    5.2.1.3 Increasing applications of RNA sequencing in transcriptomics
           5.2.2 RESTRAINTS
                    5.2.2.1 High capital investments
           5.2.3 OPPORTUNITIES
                    5.2.3.1 High growth opportunities in emerging markets
                    5.2.3.2 Increasing applications in toxicogenomics
                    5.2.3.3 Increasing focus on biomarker discovery
                    5.2.3.4 Rising focus on outsourcing
           5.2.4 CHALLENGES
                    5.2.4.1 Data management in transcriptomics research
                    5.2.4.2 Lack of effective bioinformatics tools
                    5.2.4.3 Dearth of skilled professionals
    5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
    5.4 VALUE CHAIN ANALYSIS 
          FIGURE 25 VALUE CHAIN ANALYSIS OF RNA ANALYSIS INDUSTRY: RESEARCH AND MANUFACTURING PHASES CONTRIBUTE MAXIMUM VALUE
    5.5 SUPPLY CHAIN ANALYSIS 
          FIGURE 26 MARKET: SUPPLY CHAIN ANALYSIS
    5.6 ECOSYSTEM ANALYSIS 
          TABLE 5 SUPPLY CHAIN ECOSYSTEM
    5.7 PATENT ANALYSIS 
          FIGURE 27 PATENT APPLICATIONS FOR MARKET, JUNE 2012–JUNE 2023
    5.8 LIST OF MAJOR PATENTS 
    5.9 TECHNOLOGY ANALYSIS 
          TABLE 6 COMPARISON OF MODERN RNA ANALYSIS METHODS
    5.10 PORTER’S FIVE FORCES ANALYSIS 
           TABLE 7 MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.10.1 THREAT OF NEW ENTRANTS
           5.10.2 THREAT OF SUBSTITUTES
           5.10.3 BARGAINING POWER OF SUPPLIERS
           5.10.4 BARGAINING POWER OF BUYERS
           5.10.5 COMPETITIVE RIVALRY AMONG EXISTING PLAYERS
    5.11 REGULATORY ANALYSIS 
           5.11.1 REGULATIONS FOR RNA ANALYSIS PRODUCTS
           5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 8 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 9 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 10 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    5.12 KEY CONFERENCES AND EVENTS IN 2023 
           TABLE 11 MARKET: DETAILED LIST OF CONFERENCES AND EVENTS IN 2023
    5.13 KEY STAKEHOLDERS & BUYING CRITERIA 
           5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF RNA ANALYSIS PRODUCTS
           5.13.2 BUYING CRITERIA
                     FIGURE 29 KEY BUYING CRITERIA FOR END USERS
 
6 RNA ANALYSIS MARKET, BY PRODUCT & SERVICE (Page No. - 81)
    6.1 INTRODUCTION 
          TABLE 12 RNA ANALYSIS INDUSTRY, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
    6.2 REAGENTS/CONSUMABLES 
           6.2.1 REAGENTS/CONSUMABLES TO DOMINATE MARKET DURING FORECAST PERIOD
                    TABLE 13 RNA ANALYSIS REAGENTS/CONSUMABLES MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 14 NORTH AMERICA: RNA ANALYSIS REAGENTS/CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 15 EUROPE: RNA ANALYSIS REAGENTS/CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 16 ASIA PACIFIC: RNA ANALYSIS REAGENTS/CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    6.3 INSTRUMENTS 
           6.3.1 GROWING NEED FOR ACCURATE ANALYSIS TO DRIVE ADOPTION OF AUTOMATED INSTRUMENTS
                    TABLE 17 RNA ANALYSIS INSTRUMENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 18 NORTH AMERICA: RNA ANALYSIS INSTRUMENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 19 EUROPE: RNA ANALYSIS INSTRUMENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 20 ASIA PACIFIC: RNA ANALYSIS INSTRUMENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    6.4 SOFTWARE 
           6.4.1 GROWING NEED FOR DATA MANAGEMENT AND QUALITY ENHANCEMENTS TO DRIVE DEMAND FOR SOFTWARE SOLUTIONS
                    TABLE 21 RNA ANALYSIS SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 22 NORTH AMERICA: RNA ANALYSIS SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 23 EUROPE: RNA ANALYSIS SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 24 ASIA PACIFIC: RNA ANALYSIS SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    6.5 SERVICES 
           6.5.1 INCREASING OUTSOURCING OF SERVICES TO PROPEL MARKET GROWTH
                    TABLE 25 RNA ANALYSIS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 26 NORTH AMERICA: RNA ANALYSIS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 27 EUROPE: RNA ANALYSIS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 28 ASIA PACIFIC: RNA ANALYSIS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
 
7 RNA ANALYSIS MARKET, BY TECHNOLOGY (Page No. - 95)
    7.1 INTRODUCTION 
          TABLE 29 RNA ANALYSIS INDUSTRY, BY TECHNOLOGY, 2021–2028 (USD MILLION)
    7.2 POLYMERASE CHAIN REACTION 
           7.2.1 ABILITY OF REAL-TIME PCR TO AID IN QUANTIFICATION OF LOW-COPY TRANSCRIPTS TO BOOST DEMAND
                    TABLE 30 MARKET FOR PCR TECHNOLOGY, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 31 NORTH AMERICA: MARKET FOR PCR TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 32 EUROPE: MARKET FOR PCR TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 33 ASIA PACIFIC: MARKET FOR PCR TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
    7.3 SEQUENCING 
           7.3.1 ADVANCES IN NGS MULTIPLEXING CAPABILITIES TO AID MARKET GROWTH
                    TABLE 34 MARKET FOR SEQUENCING TECHNOLOGY, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 35 NORTH AMERICA: MARKET FOR SEQUENCING TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 36 EUROPE: MARKET FOR SEQUENCING TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 37 ASIA PACIFIC: MARKET FOR SEQUENCING TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
    7.4 MICROARRAYS 
           7.4.1 WIDE ADOPTION OF MICROARRAYS IN CLINICAL DIAGNOSTICS TO SUPPORT MARKET GROWTH
                    TABLE 38 MARKET FOR MICROARRAY TECHNOLOGY, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 39 NORTH AMERICA: MARKET FOR MICROARRAY TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 40 EUROPE: MARKET FOR MICROARRAY TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 41 ASIA PACIFIC: MARKET FOR MICROARRAY TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
    7.5 RNA INTERFERENCE 
           7.5.1 TECHNOLOGICAL ADVANCEMENTS TO SUPPORT ADOPTION OF TECHNIQUE FOR DIAGNOSTICS AND THERAPEUTICS
                    TABLE 42 MARKET FOR RNA INTERFERENCE TECHNOLOGY, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 43 NORTH AMERICA: MARKET FOR RNA INTERFERENCE TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 44 EUROPE: MARKET FOR RNA INTERFERENCE TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 45 ASIA PACIFIC: MARKET FOR RNA INTERFERENCE TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
 
8 RNA ANALYSIS MARKET, BY APPLICATION (Page No. - 109)
    8.1 INTRODUCTION 
          TABLE 46 RNA ANALYSIS INDUSTRY, BY APPLICATION, 2021–2028 (USD MILLION)
    8.2 DRUG DISCOVERY 
           8.2.1 GROWING POPULARITY OF TARGETED SEQUENCING-BASED APPROACHES IN DRUG DISCOVERY TO BOOST MARKET
                    TABLE 47 MARKET FOR DRUG DISCOVERY, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 48 NORTH AMERICA: MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 49 EUROPE: MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 50 ASIA PACIFIC: MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2021–2028 (USD MILLION)
    8.3 CLINICAL DIAGNOSTICS 
           8.3.1 GROWING ADOPTION OF TRANSCRIPTOMICS FOR LARGE-SCALE GENE EXPRESSION PROFILING OF ONCOLOGICAL DISORDERS TO FUEL GROWTH
                    TABLE 51 MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 52 NORTH AMERICA: MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 53 EUROPE: MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 54 ASIA PACIFIC: MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION)
    8.4 TOXICOGENOMICS 
           8.4.1 GROWING FOCUS ON ADR STUDIES TO DRIVE ADOPTION OF TRANSCRIPTOMICS FOR SYSTEMIC TOXICOLOGY
                    TABLE 55 MARKET FOR TOXICOGENOMICS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 56 NORTH AMERICA: MARKET FOR TOXICOGENOMICS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 57 EUROPE: MARKET FOR TOXICOGENOMICS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 58 ASIA PACIFIC: MARKET FOR TOXICOGENOMICS, BY COUNTRY, 2021–2028 (USD MILLION)
    8.5 COMPARATIVE TRANSCRIPTOMICS 
           8.5.1 WIDE ADOPTION OF TRANSCRIPTIONAL PROFILES TO STUDY EVOLUTION AMONG SPECIES TO PROPEL GROWTH
                    TABLE 59 MARKET FOR COMPARATIVE TRANSCRIPTOMICS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 60 NORTH AMERICA: MARKET FOR COMPARATIVE TRANSCRIPTOMICS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 61 EUROPE: MARKET FOR COMPARATIVE TRANSCRIPTOMICS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 62 ASIA PACIFIC: MARKET FOR COMPARATIVE TRANSCRIPTOMICS, BY COUNTRY, 2021–2028 (USD MILLION)
 
9 RNA ANALYSIS MARKET, BY END USER (Page No. - 123)
    9.1 INTRODUCTION 
          TABLE 63 RNA ANALYSIS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
    9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 
           9.2.1 INCREASING INVESTMENTS FOR ONCOLOGY THERAPEUTICS TO DRIVE USE OF OMICS TECHNOLOGIES IN PHARMA & BIOTECH COMPANIES
                    TABLE 64 MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 65 NORTH AMERICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 66 EUROPE: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 67 ASIA PACIFIC: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
    9.3 HOSPITALS & DIAGNOSTIC CENTERS 
           9.3.1 USE OF WHOLE-BLOOD TRANSCRIPTOME PROFILES FOR DISEASE DIAGNOSTICS TO FAVOR MARKET GROWTH
                    TABLE 68 MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 69 NORTH AMERICA: MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 70 EUROPE: MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 71 ASIA PACIFIC: MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2021–2028 (USD MILLION)
    9.4 ACADEMIC & RESEARCH INSTITUTES 
           9.4.1 GROWING GOVERNMENT INVESTMENTS TO PROPEL MARKET GROWTH
                    TABLE 72 MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 73 NORTH AMERICA: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 74 EUROPE: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 75 ASIA PACIFIC: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
    9.5 CONTRACT RESEARCH ORGANIZATIONS 
           9.5.1 GROWING OUTSOURCING OF SERVICES BY PHARMACEUTICAL COMPANIES FOR FASTER DRUG DISCOVERY TO AID MARKET GROWTH
                    TABLE 76 MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 77 NORTH AMERICA: MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 78 EUROPE: MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 79 ASIA PACIFIC: MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
 
10 RNA ANALYSIS MARKET, BY REGION (Page No. - 135)
     10.1 INTRODUCTION 
             TABLE 80 RNA ANALYSIS INDUSTRY, BY REGION, 2021–2028 (USD MILLION)
     10.2 NORTH AMERICA 
             FIGURE 30 NORTH AMERICA: RNA ANALYSIS MARKET SNAPSHOT
             TABLE 81 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028(USD MILLION)
             TABLE 82 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
             TABLE 83 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 84 NORTH AMERICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 85 NORTH AMERICA: RNA ANALYSIS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
             10.2.1 US
                        10.2.1.1 US to dominate North American RNA analysis market during forecast period
                                       TABLE 86 US: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                       TABLE 87 US: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                       TABLE 88 US: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                       TABLE 89 US: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.2.2 CANADA
                        10.2.2.1 Improving funding and infrastructure for omics-based research to support market growth
                                       TABLE 90 CANADA: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                       TABLE 91 CANADA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                       TABLE 92 CANADA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                       TABLE 93 CANADA: RNA ANALYSIS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
             10.2.3 NORTH AMERICA: RECESSION IMPACT
     10.3 EUROPE 
             TABLE 94 EUROPE: RNA ANALYSIS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 95 EUROPE: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
             TABLE 96 EUROPE: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 97 EUROPE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 98 EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.1 GERMANY
                        10.3.1.1 Germany to hold largest share of European RNA analysis market during forecast period
                                       TABLE 99 GERMANY: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                       TABLE 100 GERMANY: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                       TABLE 101 GERMANY: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                       TABLE 102 GERMANY: RNA ANALYSIS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
             10.3.2 UK
                        10.3.2.1 Rising public and private funding for research to drive market growth
                                       TABLE 103 UK: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                       TABLE 104 UK: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                       TABLE 105 UK: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                       TABLE 106 UK: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.3 FRANCE
                        10.3.3.1 Increasing government support for omics-based research to support market growth
                                       TABLE 107 FRANCE: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                       TABLE 108 FRANCE: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                       TABLE 109 FRANCE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                       TABLE 110 FRANCE: RNA ANALYSIS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
             10.3.4 ITALY
                        10.3.4.1 Improving R&D expenditure and disease diagnostics to boost market
                                       TABLE 111 ITALY: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                       TABLE 112 ITALY: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                       TABLE 113 ITALY: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                       TABLE 114 ITALY: RNA ANALYSIS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
             10.3.5 SPAIN
                        10.3.5.1 Increasing collaborations for enhancing research to support market growth
                                       TABLE 115 SPAIN: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                       TABLE 116 SPAIN: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                       TABLE 117 SPAIN: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                       TABLE 118 SPAIN: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.6 SWITZERLAND
                        10.3.6.1 Well-established pharmaceutical industry to drive market growth
                                       TABLE 119 SWITZERLAND: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                       TABLE 120 SWITZERLAND: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                       TABLE 121 SWITZERLAND: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                       TABLE 122 SWITZERLAND: RNA ANALYSIS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
             10.3.7 REST OF EUROPE
                        TABLE 123 REST OF EUROPE: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 124 REST OF EUROPE: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 125 REST OF EUROPE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 126 REST OF EUROPE: RNA ANALYSIS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
     10.4 EUROPE: RECESSION IMPACT 
     10.5 ASIA PACIFIC 
             FIGURE 31 ASIA PACIFIC: RNA ANALYSIS MARKET SNAPSHOT
             TABLE 127 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 128 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
             TABLE 129 ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 130 ASIA PACIFIC: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 131 ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.5.1 CHINA
                        10.5.1.1 China to be fastest-growing market in Asia Pacific during forecast period
                                       TABLE 132 CHINA: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                       TABLE 133 CHINA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                       TABLE 134 CHINA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                       TABLE 135 CHINA: RNA ANALYSIS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
             10.5.2 JAPAN
                        10.5.2.1 Early adoption of technologically advanced products to drive market growth
                                       TABLE 136 JAPAN: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                       TABLE 137 JAPAN: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                       TABLE 138 JAPAN: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                       TABLE 139 JAPAN: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.5.3 INDIA
                        10.5.3.1 Increasing pharmaceutical R&D spending and government funding for research to drive market growth
                                       TABLE 140 INDIA: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                       TABLE 141 INDIA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                       TABLE 142 INDIA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                       TABLE 143 INDIA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.5.4 REST OF ASIA PACIFIC
                        TABLE 144 REST OF ASIA PACIFIC: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 145 REST OF ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 146 REST OF ASIA PACIFIC: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 147 REST OF ASIA PACIFIC: RNA ANALYSIS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
     10.6 ASIA PACIFIC: RECESSION IMPACT 
     10.7 LATIN AMERICA 
             10.7.1 GROWTH IN PHARMACEUTICAL INDUSTRY IN MEXICO TO SUPPORT MARKET GROWTH
                        TABLE 148 LATIN AMERICA: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 149 LATIN AMERICA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 150 LATIN AMERICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 151 LATIN AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
     10.8 LATIN AMERICA: RECESSION IMPACT 
     10.9 MIDDLE EAST & AFRICA 
             10.9.1 IMPROVING FOCUS ON PRECISION MEDICINE AND DISEASE GENETICS TO DRIVE MARKET GROWTH
                        TABLE 152 MIDDLE EAST & AFRICA: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 153 MIDDLE EAST & AFRICA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 154 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 155 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
     10.10 MIDDLE EAST & AFRICA: RECESSION IMPACT 
 
11 COMPETITIVE LANDSCAPE (Page No. - 192)
     11.1 INTRODUCTION 
     11.2 STRATEGIES ADOPTED BY KEY PLAYERS 
             FIGURE 32 RNA ANALYSIS MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
     11.3 REVENUE SHARE ANALYSIS 
             FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS, 2020–2022
     11.4 MARKET SHARE ANALYSIS 
             FIGURE 34 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2022
             TABLE 156 RNA ANALYSIS INDUSTRY: DEGREE OF COMPETITION
     11.5 COMPANY EVALUATION QUADRANT: KEY PLAYERS 
             FIGURE 35 MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022
             11.5.1 STARS
             11.5.2 EMERGING LEADERS
             11.5.3 PERVASIVE PLAYERS
             11.5.4 PARTICIPANTS
     11.6 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS 
             11.6.1 COMPANY PRODUCT FOOTPRINT OF COMPANIES (25 COMPANIES)
                        TABLE 157 COMPANY PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS IN MARKET
             11.6.2 REGIONAL FOOTPRINT OF COMPANIES (25 COMPANIES)
                        TABLE 158 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN MARKET
     11.7 COMPANY EVALUATION QUADRANT: STARTUPS/SMES 
             FIGURE 36 MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/ SMES, 2022
             11.7.1 PROGRESSIVE COMPANIES
             11.7.2 STARTING BLOCKS
             11.7.3 RESPONSIVE COMPANIES
             11.7.4 DYNAMIC COMPANIES
     11.8 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS 
             TABLE 159 MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
             TABLE 160 MARKET: COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS
     11.9 COMPETITIVE SCENARIO AND TRENDS 
             11.9.1 PRODUCT LAUNCHES
                        TABLE 161 MARKET: PRODUCT & SERVICE LAUNCHES, JANUARY 2020–JUNE 2023
             11.9.2 DEALS
                        TABLE 162 RNA ANALYSIS INDUSTRY: DEALS, JANUARY 2020–JUNE 2023
             11.9.3 OTHER DEVELOPMENTS
                        TABLE 163 RNA ANALYSIS MARKET: OTHER DEVELOPMENTS, JANUARY 2020–JUNE 2023
 
12 COMPANY PROFILES (Page No. - 206)
     12.1 KEY PLAYERS 
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
             12.1.1 THERMO FISHER SCIENTIFIC INC.
                        TABLE 164 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
                        FIGURE 37 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
             12.1.2 F. HOFFMANN-LA ROCHE LTD.
                        TABLE 165 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
                        FIGURE 38 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
             12.1.3 BIO-RAD LABORATORIES, INC.
                        TABLE 166 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
                        FIGURE 39 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
             12.1.4 ILLUMINA, INC.
                        TABLE 167 ILLUMINA, INC.: COMPANY OVERVIEW
                        FIGURE 40 ILLUMINA, INC.: COMPANY SNAPSHOT (2022)
             12.1.5 EUROFINS SCIENTIFIC
                        TABLE 168 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
                        FIGURE 41 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2022)
             12.1.6 AGILENT TECHNOLOGIES, INC.
                        TABLE 169 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
                        FIGURE 42 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022)
             12.1.7 CD GENOMICS
                        TABLE 170 CD GENOMICS: COMPANY OVERVIEW
             12.1.8 PROMEGA CORPORATION
                        TABLE 171 PROMEGA CORPORATION: COMPANY OVERVIEW
             12.1.9 QIAGEN N.V.
                        TABLE 172 QIAGEN N.V.: COMPANY OVERVIEW
                        FIGURE 43 QIAGEN N.V.: COMPANY SNAPSHOT (2022)
             12.1.10 DANAHER CORPORATION
                        TABLE 173 DANAHER CORPORATION: COMPANY OVERVIEW
                        FIGURE 44 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
             12.1.11 MERCK KGAA
                        TABLE 174 MERCK KGAA: BUSINESS OVERVIEW
                        FIGURE 45 MERCK KGAA: COMPANY SNAPSHOT (2022)
             12.1.12 STANDARD BIOTOOLS INC. (FLUIDIGM CORPORATION)
                        TABLE 175 STANDARD BIOTOOLS INC.: BUSINESS OVERVIEW
                        FIGURE 46 STANDARD BIOTOOLS INC.: COMPANY SNAPSHOT (2022)
             12.1.13 SEQUENTIA BIOTECH SL
                        TABLE 176 SEQUENTIA BIOTECH SL: BUSINESS OVERVIEW
             12.1.14 ACOBIOM
                        TABLE 177 ACOBIOM: BUSINESS OVERVIEW
             12.1.15 GENXPRO GMBH
                        TABLE 178 GENXPRO GMBH: BUSINESS OVERVIEW
     12.2 OTHER PLAYERS 
             12.2.1 LEXOGEN GMBH
             12.2.2 CENIX BIOSCIENCE GMBH
             12.2.3 TAKARA HOLDINGS INC.
             12.2.4 BIOMÉRIEUX SA
             12.2.5 LC SCIENCES LLC
             12.2.6 OXFORD NANOPORE TECHNOLOGIES
             12.2.7 ZYMO RESEARCH CORPORATION
             12.2.8 GENEDX
             12.2.9 PARTEK INCORPORATED
             12.2.10 BGI GROUP
 
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
 
13 APPENDIX (Page No. - 257)
     13.1 DISCUSSION GUIDE 
     13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     13.3 CUSTOMIZATION OPTIONS 
     13.4 RELATED REPORTS 
     13.5 AUTHOR DETAILS 

This study involved four major activities in estimating the current size of the RNA analysis market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. The top-down and other approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the RNA analysis market. The secondary sources referred to for this research study include publications from government and private sources such as the Association of Biomolecular Resource Facilities, the Journal of the American Chemical Society, the Protein Science Society of Japan (PSSJ), the National Institutes of Health (NIH), World Health Organization (WHO), Analytical and Life Science Systems Association (ALSSA), Advanced Medical Technology Association (AdvaMed), American Association for Clinical Chemistry (AACC), American Public Health Association (APHA), European Diagnostic Manufacturers Association (EDMA), Biotechnology Innovation Organization (BIO), European Federation of Biotechnology (EFB), Journal of Biomedical Materials Research,       Office for National Statistics (ONS), and Organisation for Economic Co-operation and Development (OECD), Company Websites, Annual Reports, SEC Filings, Press Releases, Investor Presentations, Journals, Expert Interviews, MarketsandMarkets Analysis. Secondary data was collected and analyzed to arrive at the overall size of the global RNA analysis market, which was then validated by primary research.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

RNA analysis Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

A top-down approach was used to estimate and validate the total size of the RNA analysis market. This method was also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive secondary research
  • The revenues generated from the RNA analysis business of leading players have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Global RNA analysis market size: Top-Down Approach

RNA analysis Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Data Triangulation

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Transcriptomics is the study of the complete set of RNAs (transcriptomes) encoded by the genome of a specific cell or organism at a specific time or under a specific set of conditions. In the healthcare industry, transcriptomics technologies have applications in clinical diagnostics, drug discovery, and toxicogenomic research. The market study includes the assessment of various products & services, technology, application, and end users in RNA analysis.

Key Stakeholders

  • Life sciences instrumentation and reagent companies
  • Pharmaceutical and biotechnology companies
  • Proteomics database and software providers
  • RNA analysis service providers
  • Research and consulting firms
  • Academic medical centers
  • Government research organizations 
  • Clinical research institutes
  • Contract Research Organizations

Report Objectives

  • To define, describe, and forecast the RNA analysis market by product & service, technology, application, end-user, and region
  • To provide detailed information about the major factors influencing the market growth (drivers, restraints, opportunities, and challenges)
  • To strategically analyze micro markets with respect to the individual growth trends, prospects, and contributions to the overall market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments in North America, Europe, Asia Pacific,  Latin America, and the Middle East & Africa
  • To profile the key players and comprehensively analyze their market shares and core competencies in the global RNA analysis market
  • To track and analyze competitive developments such as product & service launches, partnerships, collaborations, agreements, expansions, and acquisitions in the global RNA analysis market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Geographic Analysis

  • Further Breakdown Of The Rest Of Europe Rna Analysis Market Into Respective Countries
  • Further Breakdown Of The Rest Of Asia Pacific Rna Analysis Market Into Respective Countries
  • Further Breakdown Of The Rest Of Latin America Rna Analysis Market Into Respective Countries

Company Information

  • Detailed analysis and profiling of additional market players (Up to 5)

Company Information

  • An additional five company profiles
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization
Report Code
BT 2766
Published ON
Jul, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the RNA Analysis Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback